|
WO2017031280A1
|
|
Fusion proteins that include dengue antigens and methods of use
|
|
WO2014168948A2
|
|
Clostridium difficile compositions and methods of use
|
|
WO2014130938A1
|
|
Particle formulations for delivery of tlr agonists and antigens
|
|
US2014065177A1
|
|
Fusion proteins and methods of use
|
|
WO2013066365A1
|
|
Immunologic constructs and methods
|
|
EP2681246A2
|
|
Tetravalent and mixed head bivalent dengue vaccine
|
|
WO2012115715A2
|
|
Compositions with enhanced immunogenicity and/or reduced reactogenicity and methods of use
|
|
MX2012007916A
|
|
Methods and compositions for providing protective immunity in the elderly.
|
|
AU2009236585A1
|
|
Deletion mutants of flagellin and methods of use
|
|
WO2009073133A1
|
|
Compositions of toll-like receptor agonists and papillomavirus antigens and uses thereof
|
|
EP3011969A1
|
|
Compositions that include hemagglutinin, methods of making and methods of use thereof
|
|
CN101394864A
|
|
Compositions that include hemagglutinin, methods of making and methods of use thereof
|
|
WO2007078879A2
|
|
Lipopeptide compositions and methods of use thereof
|
|
WO2007053455A2
|
|
Polypeptide ligans for toll-like receptor 4 (tlr4)
|
|
WO2007053428A2
|
|
Method to identify polypeptide-toll-like receptor (tlr) ligands
|
|
WO2006083792A2
|
|
Novel polypeptide ligands for toll-like receptor 2 (tlr2)
|
|
CA2596248A1
|
|
Method to identify polypeptide toll-like receptor (tlr) ligands
|
|
SG158894A1
|
|
Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
|
|
CN101111514A
|
|
Compositions comprising pathogen-associated molecular patterns and antigens and their use to stimulate an immune response
|
|
MX2007007586A
|
|
Compositions of influenza viral proteins and methods of use thereof.
|
